Biogen [BIIB] vs Pfizer [PFE] Detailed Stock Comparison
Biogen
NASDAQ
Loading...
Pfizer
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Biogen wins in 13 metrics, Pfizer wins in 6 metrics, with 0 ties. Biogen appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Biogen | Pfizer | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 13.19 | 13.40 | Biogen |
| Price-to-Book Ratio | 1.15 | 1.62 | Biogen |
| Debt-to-Equity Ratio | 37.40 | 69.70 | Biogen |
| PEG Ratio | 8.27 | 0.00 | Pfizer |
| EV/EBITDA | 7.50 | 7.88 | Biogen |
| Profit Margin (TTM) | 15.31% | 16.84% | Pfizer |
| Operating Margin (TTM) | 34.61% | 28.68% | Biogen |
| EBITDA Margin (TTM) | 34.61% | 28.68% | Biogen |
| Return on Equity | 9.13% | 12.17% | Pfizer |
| Return on Assets (TTM) | 5.62% | 5.25% | Biogen |
| Free Cash Flow (TTM) | $2.52B | $9.84B | Pfizer |
| Dividend Yield | N/A | 5.32% | N/A |
| 1-Year Return | -32.14% | -10.93% | Pfizer |
| Price-to-Sales Ratio (TTM) | 2.02 | 2.26 | Biogen |
| Enterprise Value | $24.16B | $193.07B | Pfizer |
| EV/Revenue Ratio | 2.42 | 3.03 | Biogen |
| Gross Profit Margin (TTM) | 77.13% | 74.22% | Biogen |
| Revenue per Share (TTM) | $68 | $11 | Biogen |
| Earnings per Share (Diluted) | $10.45 | $1.89 | Biogen |
| Beta (Stock Volatility) | 0.13 | 0.44 | Biogen |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Biogen vs Pfizer Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Biogen | 0.09% | 3.10% | 13.40% | 9.70% | -1.08% | -7.25% |
| Pfizer | 1.42% | 2.51% | 6.10% | 11.72% | -2.13% | -3.27% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Biogen | -32.14% | -29.95% | -50.57% | -54.19% | 154.80% | 238.90% |
| Pfizer | -10.93% | -45.02% | -28.44% | -16.94% | 68.57% | 9.02% |
Performance & Financial Health Analysis: Biogen vs Pfizer
| Metric | BIIB | PFE |
|---|---|---|
| Market Information | ||
| Market Cap | $20.21B | $143.96B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 1,259,084 | 38,939,600 |
| 90 Day Avg. Volume | 1,387,041 | 42,862,537 |
| Last Close | $139.12 | $25.74 |
| 52 Week Range | $110.04 - $207.59 | $20.92 - $30.43 |
| % from 52W High | -32.98% | -15.41% |
| All-Time High | $480.18 (Mar 16, 2015) | $61.71 (Dec 20, 2021) |
| % from All-Time High | -71.03% | -58.29% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.07% | 0.10% |
| Quarterly Earnings Growth | 0.09% | 69.98% |
| Financial Health | ||
| Profit Margin (TTM) | 0.15% | 0.17% |
| Operating Margin (TTM) | 0.35% | 0.29% |
| Return on Equity (TTM) | 0.09% | 0.12% |
| Debt to Equity (MRQ) | 37.40 | 69.70 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $120.29 | $15.60 |
| Cash per Share (MRQ) | $18.82 | $2.33 |
| Operating Cash Flow (TTM) | $2.12B | $15.19B |
| Levered Free Cash Flow (TTM) | $2.27B | $16.02B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 5.32% |
| Last 12-Month Dividend | N/A | $1.27 |
Valuation & Enterprise Metrics Analysis: Biogen vs Pfizer
| Metric | BIIB | PFE |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 13.19 | 13.40 |
| Forward P/E | 8.27 | 8.64 |
| PEG Ratio | 8.27 | 0.00 |
| Price to Sales (TTM) | 2.02 | 2.26 |
| Price to Book (MRQ) | 1.15 | 1.62 |
| Market Capitalization | ||
| Market Capitalization | $20.21B | $143.96B |
| Enterprise Value | $24.16B | $193.07B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.42 | 3.03 |
| Enterprise to EBITDA | 7.50 | 7.88 |
| Risk & Other Metrics | ||
| Beta | 0.13 | 0.44 |
| Book Value per Share (MRQ) | $120.29 | $15.60 |
Financial Statements Comparison: Biogen vs Pfizer
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BIIB | PFE |
|---|---|---|
| Revenue/Sales | $2.43B | $13.72B |
| Cost of Goods Sold | $629.30M | $2.85B |
| Gross Profit | $1.80B | $10.87B |
| Research & Development | $434.10M | $2.20B |
| Operating Income (EBIT) | $625.20M | $4.43B |
| EBITDA | $831.80M | $6.48B |
| Pre-Tax Income | $311.20M | $2.79B |
| Income Tax | $70.70M | $-189.00M |
| Net Income (Profit) | $240.50M | $2.97B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BIIB | PFE |
|---|---|---|
| Cash & Equivalents | $2.60B | $1.43B |
| Total Current Assets | $7.63B | $45.86B |
| Total Current Liabilities | $5.30B | $36.45B |
| Long-Term Debt | $4.87B | $56.82B |
| Total Shareholders Equity | $16.98B | $90.64B |
| Retained Earnings | $19.50B | $119.59B |
| Property, Plant & Equipment | $6.22B | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BIIB | PFE |
|---|---|---|
| Operating Cash Flow | $518.90M | $3.91B |
| Capital Expenditures | $-37.10M | $-564.00M |
| Free Cash Flow | $212.20M | $1.77B |
| Debt Repayment | $0 | $-2.43B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BIIB | PFE |
|---|---|---|
| Shares Short | 3.96M | 107.78M |
| Short Ratio | 2.97 | 2.67 |
| Short % of Float | 0.03% | 0.02% |
| Average Daily Volume (10 Day) | 1,259,084 | 38,939,600 |
| Average Daily Volume (90 Day) | 1,387,041 | 42,862,537 |
| Shares Outstanding | 145.72M | 5.67B |
| Float Shares | 146.23M | 5.68B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.93% | 0.67% |
Dividend Analysis & Yield Comparison: Biogen vs Pfizer
| Metric | BIIB | PFE |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.27 |
| Last 12-Month Dividend Yield | N/A | 5.32% |
| 3-Year Avg Annual Dividend | N/A | $1.52 |
| 3-Year Avg Dividend Yield | N/A | 1.27% |
| 3-Year Total Dividends | N/A | $4.55 |
| Ex-Dividend Date | N/A | Jan 24, 2025 |